Investors lap up shares of firms that may benefit from Monkeypox

Shares of vaccine producers, antiviral drug makers and protective equipment manufacturers are in demand as investors tap a strategy that delivered gains during the coronavirus pandemic

Monkeypox
Premium

Monkeypox (Illustration: Reuters)

Abhishek Vishnoi, Bre Bradham & Jonas Ekblom | Bloomberg
As health authorities all over the globe search for ways to stop the monkeypox outbreak, investors are snapping up shares of companies that could benefit from the race to quell the disease. 

Shares of vaccine producers, antiviral drug makers and protective equipment manufacturers are in demand as investors tap a strategy that delivered gains during the coronavirus pandemic. Biotechnological company Bavarian Nordic A/S and pharmaceutical firm Siga Technologies Inc. are among the stocks in focus as well as medical tools supplier Precision System Science Co.

While nowhere as severe as the Covid-19 outbreak, the spread of monkeypox infections across more than 70 countries in just a few months has prompted the World Health Organization to declare it as a global emergency. This

Also Read

India working on indigenous kit to test monkeypox as cases on the rise

Siga Tech's tecovirimat drug could help counter monkeypox, says study

No need to panic over monkeypox, have taken steps to curb it: Kerala govt

Monkeypox outbreak: Delhi reports India's 4th case, Centre in a huddle

India considering to develop monkeypox vaccine; SII CEO says no rush

Dollar rallies from three-week lows as US data shows pick-up in inflation

Oil rally to stall as recession risks counter tight supplies, says poll

Nasdaq, S&P 500 rise on upbeat forecasts from Apple, Amazon

Yen shoots for best month in years as growth concerns bring US yields down

Dollar pares gains as US economic growth contracts for second quarter

First Published: Aug 01 2022 | 12:13 AM IST

Explore News

To read the full story, subscribe to BS Premium now, at just Rs 249/ month.

Key stories on business-standard.com are available only to BS Premium subscribers.

Register to read more on Business-Standard.com